Heart failure and dyslipidemia: the role of statins Heart failure is part of the progression of heart diseases in the cardiovascular continuum. The treatment with the HMGCoA inhibitors (statins) has shown benefit in  reducing mortality and morbidity in patients with dyslipidemia and coronary artery disease. In addition, in patients with heart failure, benefit of statins has also been reported but only in observational, retrospective and post-hoc analysis of small randomized trials. Recently, with new data available from randomized, doubleblind, placebo-controlled trials with thousands of patients, statin therapy failed to show any beneficial effect on outcome in heart failure patients despite significant reductions in low-density lipoprotein and high sensitivity C- reactive protein. In this review, we discuss unresolved issues and recent findings regarding the use of statins in heart failure.

heart failure; statins